ARS Pharmaceuticals Ownership | Who Owns ARS Pharmaceuticals?


OverviewForecastRevenueFinancialsChartTranscripts

ARS Pharmaceuticals Ownership Summary


ARS Pharmaceuticals is owned by 36.33% institutional investors, 16.29% insiders, and 47.38% retail investors. Ra capital management is the largest institutional shareholder, holding 11.02% of SPRY shares. State Street® SPDR® S&P® Biotech ETF is the top mutual fund, with 2.42% of its assets in ARS Pharmaceuticals shares.

SPRY Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockARS Pharmaceuticals36.33%16.29%47.38%
SectorHealthcare Stocks 35.58%11.87%52.55%
IndustryBiotech Stocks 35.75%11.83%52.41%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Ra capital management10.86M11.02%$87.21M
Orbimed advisors8.29M8.41%$66.56M
Rubric capital management lp8.00M8.12%$64.24M
Deerfield management company, l.p. (series c)7.50M7.61%$60.26M
Millennium management5.98M6.07%$48.04M
Blackrock funding, inc. /de5.01M5.09%$40.25M
Abrdn4.11M4.17%$33.03M
Sr one capital management, lp4.01M4.07%$32.22M
State street3.64M3.70%$29.27M
Vanguard group3.51M3.55%$40.88M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Sr one capital management, lp4.01M3.52%$32.22M
Tyro capital management2.97M2.59%$23.84M
Bioimpact capital1.30M2.14%$13.10M
Nextech invest936.73K1.60%$9.88M
Orbimed advisors8.29M1.32%$66.56M
Ra capital management10.86M0.92%$87.21M
Deerfield management company, l.p. (series c)7.50M0.71%$60.26M
Investment management associates inc /adv359.07K0.69%$2.88M
Rubric capital management lp8.00M0.68%$64.24M
American assets7.00K0.57%$1.71M

Top Buyers

HolderShares% AssetsChange
Millennium management5.98M0.02%2.81M
Rubric capital management lp8.00M0.68%1.80M
Qube research1.03M0.01%1.03M
Tyro capital management2.97M2.59%973.75K
Franklin resources3.28M0.01%735.45K

Top Sellers

HolderShares% AssetsChange
Adage capital partners gp---1.73M
Casdin capital---1.60M
Southpoint capital advisors lp---1.50M
Wellington management group llp---1.43M
Octagon capital advisors lp---1.35M

New Positions

HolderShares% AssetsChangeValue
Qube research1.03M0.01%1.03M$10.40M
Vanguard fiduciary trust446.31K0.00%446.31K$3.58M
Tejara capital210.40K0.56%210.40K$1.69M
Landscape capital management168.79K0.09%168.79K$1.36M
Exoduspoint capital management, lp96.09K0.01%96.09K$771.63K

Sold Out

HolderChange
National bank of canada /fi/-1.00
Principal securities-17.00
True wealth design-21.00
Stephens consulting-30.00
Capital performance advisors llp-33.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 2026128-34.36%35,806,185-59.76%360.45%62-32.61%35-40.68%
Dec 31, 2025144-28.00%49,264,084-41.09%490.69%69-39.47%42-10.64%
Sep 30, 20251961.03%83,443,647-1.27%841.15%111-1.77%46-
Jun 30, 20251921.59%84,508,65610.87%851.42%11112.12%46-16.36%
Mar 31, 20251888.05%76,205,3346.92%771.44%992.06%5420.00%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
State Street® SPDR® S&P® Biotech ETF2.40M2.42%-24.38K
Vanguard US Total Market Shares ETF1.86M1.90%-
abrdn Healthcare Opportunities1.78M1.80%-
Vanguard Total Stock Mkt Idx Inv1.75M1.76%-
Franklin Biotechnology Discv A(acc)USD1.56M1.57%-
abrdn Healthcare Investors1.55M1.56%-
iShares Russell 2000 ETF1.39M1.40%11.75K
Baron Discovery Strategy1.07M1.08%-
Baron Discovery Institutional1.07M1.08%-
AB Small Cap Growth A1.05M1.06%-56.95K

Recent Insider Transactions


DateNameRoleActivityValue
Nov 13, 2025Dorsey Brian Chief Operating OfficerSell$190.05K
Nov 12, 2025Chakma Justin Chief Business OfficerSell$267.36K
Nov 12, 2025Chakma Justin Chief Business OfficerSell$1.21M
Aug 21, 2025Lowenthal Richard E PRESIDENT AND CEOSell$724.35K
Aug 21, 2025Scott Kathleen D. Chief Financial OfficerSell$187.50K

Insider Transactions Trends


DateBuySell
2026 Q2--
2026 Q1--
2025 Q4-3
2025 Q3-5
2025 Q2-6

SPRY Ownership FAQ


Who Owns ARS Pharmaceuticals?

ARS Pharmaceuticals shareholders are primarily institutional investors at 36.33%, followed by 16.29% insiders and 47.38% retail investors. The average institutional ownership in ARS Pharmaceuticals's industry, Biotech Stocks , is 35.75%, which ARS Pharmaceuticals exceeds.

Who owns the most shares of ARS Pharmaceuticals?

ARS Pharmaceuticals’s largest shareholders are Ra capital management (10.86M shares, 11.02%), Orbimed advisors (8.29M shares, 8.41%), and Rubric capital management lp (8M shares, 8.12%). Together, they hold 27.54% of ARS Pharmaceuticals’s total shares outstanding.

Does Blackrock own ARS Pharmaceuticals?

BlackRock is not among the top 10 institutional shareholders of ARS Pharmaceuticals.

Who is ARS Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Sr one capital management, lp is ARS Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 3.52% of its assets in 4.01M ARS Pharmaceuticals shares, valued at 32.22M$.

Who is the top mutual fund holder of ARS Pharmaceuticals shares?

State Street® SPDR® S&P® Biotech ETF is the top mutual fund holder of ARS Pharmaceuticals shares, with 2.42% of its total shares outstanding invested in 2.4M ARS Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools